Using local memory circuits provides for precise control of the currents delivered to individual electrodes on the array, while minimizing the utilization of "off-chip" circuitry and overall system costs. The electric potential is controlled at each of the NanoChip's 400 test sites to move and concentrate DNA or RNA, providing accuracy, speed and flexibility for developing molecular diagnostic tests. Storing critical voltage information allows for precise control of the biological molecules during analysis and increases data management efficiency by tracking test site activation and array usage directly on the electronic microarray cartridge.
"This addition to our growing intellectual property portfolio illustrates our ability to develop differentiated advanced diagnostic products that add value to the company and to research and clinical laboratory customers," said Howard C. Birndorf, Nanogen chairman of the board and CEO.
This new patent expands Nanogen's intellectual property portfolio to include 114 patents issued in the U.S.
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and relia ble NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com.